19 June 2013
Keywords: Biotie Therapies, Newron Pharma, M&A, CNS drug development
Article | 27 September 2011
In a second acquisition this year, Finland-based biotech company Biotie Therapies (OMX: BTH1V) has entered into an agreement to ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
27 September 2011
28 September 2011
18 June 2013
© 2013 thepharmaletter.com